Want to see DE:SBS full AI Analyst Report?
Top Page
STRATEC Biomedical
(XETRA:SBS)
Select Model
Select Model
Rating:60Neutral
Price Target:
€23.00
▲(16.75% Upside)
Action:Reiterated
Date:08/17/26
DE:SBS scores highest on technical momentum (price above key moving averages with positive MACD), but the overall score is held back by weakened financial performance (multi-year revenue decline and profitability near break-even). Confirmed guidance and improved cash flow from the latest earnings call support the outlook, while valuation remains constrained by negative earnings despite a moderate dividend yield.
Positive Factors
Systems revenue growth
Strong systems growth in immunoassay, molecular diagnostics and immunohematology supports STRATEC’s core platform business. Higher instrument demand can expand production volumes, deepen customer relationships and create future consumables and lifecycle-service revenue.
Negative Factors
Revenue contraction and near-break-even profitability
Several years of declining revenue and compressed profitability weaken the earnings base and reduce the company’s ability to fund growth internally. Near-zero net income also makes results more sensitive to product mix, volume recovery and execution setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Systems revenue growth
Strong systems growth in immunoassay, molecular diagnostics and immunohematology supports STRATEC’s core platform business. Higher instrument demand can expand production volumes, deepen customer relationships and create future consumables and lifecycle-service revenue.
Read all positive factors
STRATEC Biomedical (SBS) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€259.53M
Dividend Yield2.78%
Average Volume (3M)15.55K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue GrowthN/A
EPS GrowthN/A
CountryDE
Employees1,395
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio11.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.09
P/FCF Ratio-28.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.00Price Target Upside42.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.45
Revenue Forecast (FY)€267.07M
STRATEC Biomedical Business Overview & Revenue Model
Company Description
Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumenta...
How the Company Makes Money
STRATEC primarily makes money as an OEM/contract development and manufacturing partner for diagnostics and life science companies by (1) developing instrument platforms and (2) producing and supporting them over their commercial lifecycles. Key re...
STRATEC Biomedical Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Neutral
The call presented a mixed but constructive picture: significant operational and financial positives (a material Q2 operational recovery, a strong cash-flow turnaround, systems revenue growth and debt reduction) were offset by meaningful short-term headwinds (an H1 revenue decline, an unusually weak consumables/maintenance parts trend, elevated inventories, supply-chain pressures and continued customer order volatility). Management confirmed 2026 guidance and set credible multi-year growth and margin targets, while emphasizing cost discipline and product pipeline execution. Given the sizable cash-flow and margin improvements together with confirmed guidance, but acknowledging persistent near-term demand and supply risks, the tone is cautiously optimistic.Positive Updates
Strong Q2 recovery and operational leverage
Q2 adjusted EBIT increased by more than 125% to EUR 7.0 million; adjusted EBIT margin improved from 5.4% in Q1 to 11.9% in Q2, demonstrating operational leverage as volumes recovered.
Negative Updates
H1 revenue decline and unfavorable product mix
H1 revenue of EUR 112.5 million, a nominal decline of 5.1% (or -3.3% on a constant currency basis). The mix shifted away from higher-margin service parts and consumables, which pressured margins (adjusted EBIT margin 6.9% vs 7.2% prior year).
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Q2 recovery and operational leverage
Q2 adjusted EBIT increased by more than 125% to EUR 7.0 million; adjusted EBIT margin improved from 5.4% in Q1 to 11.9% in Q2, demonstrating operational leverage as volumes recovered.
Read all positive updates
Company Guidance
STRATEC confirmed its 2026 guidance, calling for medium‑to‑high single‑digit sales growth on a constant‑currency basis with the year highly back‑end loaded (Q4 historically contributes ~30–33% of annual revenue and management expects Q4 toward the top end of that range, with Q3 roughly in the same ballpark as Q2); adjusted EBIT margin for 2026 is expected to be approximately at last year’s ~10% level, CapEx is guided to a 6.5–8.5%‑of‑sales corridor (management expects to be at the lower edge), and there is a continuing focus on working‑capital efficiency and cash‑flow improvement; medium‑term targets are 2025–2028 revenue CAGR of 6–8% and 2028–2030 CAGR of 10–12%, with adjusted EBIT margin of at least 13% by 2028 and at least 15% by 2030—guidance is underpinned by H1 results (revenue €112.5m, down 5.1% nominal / 3.3% cc; H1 adjusted EBIT €7.7m, 6.9% margin; free cash flow €23.5m) and a net debt position of €96.7m (net debt / LTM EBITDA 2.9x).STRATEC Biomedical Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 244.81M | 250.86M | 257.62M | 270.41M | 274.63M | 287.33M |
| Gross Profit | 57.70M | 64.22M | 76.39M | 68.16M | 79.49M | 87.71M |
| EBITDA | 31.43M | 27.19M | 47.34M | 43.16M | 57.53M | 66.52M |
| Net Income | -395.00K | -242.00K | 16.02M | 15.37M | 29.22M | 39.96M |
Balance Sheet | ||||||
| Total Assets | 410.73M | 443.38M | 445.06M | 466.58M | 397.50M | 368.52M |
| Cash, Cash Equivalents and Short-Term Investments | 19.03M | 24.40M | 48.73M | 34.22M | 24.07M | 48.72M |
| Total Debt | 115.72M | 132.13M | 130.53M | 141.37M | 87.15M | 85.30M |
| Total Liabilities | 172.29M | 206.06M | 202.53M | 233.25M | 172.32M | 162.77M |
| Stockholders Equity | 238.44M | 237.32M | 242.53M | 233.33M | 225.18M | 205.76M |
Cash Flow | ||||||
| Free Cash Flow | 26.33M | -9.71M | 30.52M | 2.00M | -8.74M | 43.24M |
| Operating Cash Flow | 35.05M | -433.00K | 48.71M | 19.43M | 10.28M | 63.47M |
| Investing Cash Flow | -14.05M | -16.80M | -15.97M | -44.16M | -19.00M | -20.13M |
| Financing Cash Flow | -21.31M | -6.30M | -20.30M | 35.44M | -14.11M | -34.33M |
STRATEC Biomedical Technical Analysis
Positive
19.70
Price Trends
19.19
Positive
18.11
Positive
19.31
Positive
Market Momentum
0.70
Negative
61.62
Neutral
49.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SBS, the sentiment is Positive. The current price of 19.7 is below the 20-day moving average (MA) of 20.61, above the 50-day MA of 19.19, and above the 200-day MA of 19.31, indicating a bullish trend. The MACD of 0.70 indicates Negative momentum. The RSI at 61.62 is Neutral, neither overbought nor oversold. The STOCH value of 49.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:SBS.
STRATEC Biomedical Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.78B | 12.08 | 9.79% | 2.82% | 6.37% | 71.55% | |
70 Outperform | €44.61B | 20.11 | 12.00% | 2.85% | -0.92% | 2.06% | |
67 Neutral | €839.12M | 16.85 | 19.49% | 1.65% | 4.42% | 35.68% | |
60 Neutral | €259.53M | -540.00 | -1.37% | 3.05% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €949.85M | -2.93 | -23.57% | 0.15% | 14.00% | -391.94% |
* General Sector Average
DE:SBS
STRATEC Biomedical
21.65
-3.34
-13.35%
DE:DRW8
Draegerwerk AG & Co. KGaA
82.20
27.72
50.87%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
13.65
-3.58
-20.79%
DE:SIS
First Sensor
54.00
-3.51
-6.10%
DE:GXI
Gerresheimer
27.60
-18.40
-40.00%
DE:SHL
Siemens Healthineers AG
40.20
-6.65
-14.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.